| Similar Articles |
|---|
 |
The Motley Fool
January 25, 2011
Brian Orelli |
FDA Approved -- Now Will It Sell? There's still plenty of uncertainty in Clinical Data's shares.   |
The Motley Fool
September 30, 2010
Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
The Motley Fool
May 18, 2011
Frank Vinluan |
Targacept's $75M Stock Offering Targets Cognitive Disorders R&D AstraZeneca bailed, but Targacept keeps on trucking. |
The Motley Fool
February 22, 2011
Ryan McBride |
Forest Labs Snaps Up Clinical Data This deal is the latest proof that drug developers with FDA-approved treatments remain hot buyout targets in a pharma industry that is starved for new products to replace brand-name drugs. |
The Motley Fool
March 23, 2009
Brian Orelli |
Good News for Eli Lilly's Depression Drug Eli Lilly announces that the Food and Drug Administration has expanded the label of Symbyax to treat patients with treatment-resistant depression, meaning they haven't been helped by at least two other drugs. |
The Motley Fool
December 1, 2008
Brian Orelli |
It's Wait Until Next Year for These Drugmakers Drugs from AstraZeneca and Eli Lilly face delays because of the FDA. Both plan to resubmit their applications for approval in the first half of next year, but the delays likely will have different effects on the companies. |
Chemistry World
February 26, 2008
James Mitchell Crow |
Q and A: Do Antidepressants Work? A widely-reported analysis of clinical trial data for Prozac and related antidepressant drugs has claimed that the medicines work little better than chemically-inactive placebos in all but the most severely depressed patients. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
January 18, 2012
Sean Williams |
This Company is Quickly Approaching the Patent Cliff Earnings exceed expectations at drug manufacturer Forest Laboratories, but worries about future sales mount. |
The Motley Fool
November 8, 2011
David Williamson |
Biotech Pops, Drops, and Break-Ups Highlighting the day's health-care stories critical to investors. |
The Motley Fool
April 9, 2009
Brian Orelli |
The Side Effects of Competition In the pharmaceutical business, it's often the competitors that determine how bad the side effects can be. |
The Motley Fool
October 10, 2011
Frank Vinluan |
TRGT Tries Again With Alzheimer's Disease Drug Candidate A Targacept compound that has been studied in a range of cognitive disorders with drug partner AstraZeneca has started in mid-stage clinical studies as a potential new Alzheimer's disease treatment. |
The Motley Fool
July 30, 2007
Brian Orelli |
Glaxo Puffs Up Targacept In the weird world of drug partnerships, GlaxoSmithKline, maker of antismoking nicotine patches, is teaming up with Targacept to investigate the positive effects of nicotine. Investors, take note. |
BusinessWeek
April 26, 2004
Carol Marie Cropper |
A Cloud Over Antidepressants Do some popular drugs cause suicidal behavior in teens? |
The Motley Fool
April 27, 2006
Stephen D. Simpson |
Investors Get Starry-Eyed for AstraZeneca Investors, while this British drug giant is getting its due from the market now in response to strong earnings, positive guidance, and more confidence in the future portfolio of drugs, remember to do your own due diligence first. |
The Motley Fool
May 21, 2009
Robert Steyer |
The AstraZeneca Dilemma Can AstraZeneca produce enough new drugs to offset a series of upcoming patent expirations? |
The Motley Fool
January 28, 2010
Brian Orelli |
The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren. |
The Motley Fool
October 30, 2009
Brian Orelli |
Of One-Time Gains and Pipelines AstraZeneca's earnings report illustrates the nature of polar opposites with one-time gains and new drugs. One is to be largely ignored, while the other will drive the drugmaker's future. |
BusinessWeek
January 31, 2005
Kerry Capell |
No Relief For AstraZeneca More bad news about potential blockbusters weakens Europe's third-largest drugmaker. Analysts say the only thing keeping Astra's shares from going into free fall is the mounting speculation that GSK might make a play for the troubled drugmaker. |
The Motley Fool
February 2, 2006
Stephen D. Simpson |
AstraZeneca: Of Patents and Pipelines Losing Toprol-XL would be a blow, but not a fatal one. So what to do with AstraZeneca's stock? It might not be as cheap as Pfizer or Abbott Labs, but if the pipeline works out, it still seems like there's money to be made here. |
The Motley Fool
December 28, 2005
Stephen D. Simpson |
AstraZeneca, Reloaded In an attempt to shore up a soft pipeline, AstraZeneca has gotten very busy looking for partners. Investors, this is not the most attractive stock in the sector, but not a horrible pick, either. |
Reason
October 2005
Maia Szalavitz |
In Defense of Happy Pills While psychotherapy validated by research has its place, there is no convincing reason why it should be considered inherently superior to drugs. Pleasure can be just as important for emotional recovery and growth as pain, if not more so. |
Managed Care
June 2006
Martin Sipkoff |
Limiting Access to SSRIs Does More Harm Than Good Despite the higher costs of SSRIs, compared to older antidepressants, limiting members' access can lead to undertreated depression. |
The Motley Fool
July 30, 2010
Cliff D'Arcy |
Which Is the Better Big Pharma? AstraZeneca is having a good 2010 -- and its shares are enjoying a great run, too. Here's how it compares to GlaxoSmithKline. |
AskMen.com
January 6, 2001
Joshua Levine |
Dealing With Depression Clinical depression is an illness characterized by a cluster of feelings, thoughts and behaviors that are strikingly different from a person's normal range of feeling and functioning... |
ifeminists
December 28, 2005
Tony Zizza |
If Depression Hurts, Eli Lilly Is Killing Us Eli Lilly's latest marketing campaign is a form of propaganda that speaks to how low Big Pharma will go to keep Americans in chemical handcuffs. |
The Motley Fool
October 30, 2008
Brian Orelli |
What's on Deck for AstraZeneca? The drugmaker increases EPS by cutting costs, but it's the next move that will count the most. |
Scientific American
August 2008
Christine Soares |
Nicotine Replacement Drug's Bad Trip Pfizer's smoking-cessation aid tied to psychiatric episodes. |
The Motley Fool
December 26, 2011
Matt Koppenheffer |
Last Week's Biggest Stock Laggards The market roared ahead last week, but some stocks and sectors weren't able to keep up with the rest of the market. |
